Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13
Vaxart to Present at the Citizens Life Sciences Conference
Express News | Vaxart Inc - Topline Data From Phase 1 Trial Expected Mid-2025
Express News | Vaxart Completes Enrollment in Phase 1 Trial for Its Norovirus Oral Pill Vaccine Candidate
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Vaxartto Present at World Vaccine Congress Washington 2025 on April 23
Prelude to increased tariffs? The Trump administration has initiated a Section 232 investigation into pharmaceuticals and Semiconductors.
① The USA government disclosed on Monday that it has launched an investigation into the impact of imported Pharmaceuticals and Semiconductors on National Security; ② This is widely seen as a prelude to imposing tariffs on prescription drugs and Semiconductors, and it could further escalate the trade war initiated by the USA.
B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Cuts Target Price to $2
B. Riley Securities Maintains Buy on Vaxart, Lowers Price Target to $2
Vaxart Analyst Ratings
Express News | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Vaxart's Earnings Call: Revenue Soars Amid COVID-19 Hurdles
Express News | Vaxart Inc: Entered Into at the Market Offering Agreement, to Offer up to $50 Million of Common Stock - SEC Filing
Q4 2024 Vaxart Inc Earnings Call
Vaxart Reports 2024 Financial Results and Vaccine Progress
Earnings Call Summary | Vaxart(VXRT.US) Q4 2024 Earnings Conference
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates